Leukocyte migration inhibitory factor production by activated lymphocytes representing immunological memory or virus-receptor interaction: response of T cell subsets to Epstein-Barr virus nuclear antigen, response of B cells to UV inactivated Epstein-Barr virus.

[1]  G. Klein,et al.  Production of leukocyte migration inhibitory factor (LIF) in human lymphocyte subsets exposed to polyclonal activators. , 1984, Cellular immunology.

[2]  G. Klein,et al.  Epstein-Barr virus susceptibility of normal human B lymphocyte populations , 1984, The Journal of experimental medicine.

[3]  G. Klein,et al.  EGNA-specific LIF production of human lymphocyte subsets. , 1984, Cellular immunology.

[4]  P. Hoffman,et al.  Lymphokine Production in T‐Lymphocyte Subsets Defined by Active E‐Rosette Formation , 1982, Scandinavian journal of immunology.

[5]  M. Masucci,et al.  Human blood lymphocyte subsets separated on the basis of nylon adherence, SRBC and EA rosetting: natural cytotoxicity and characterization with monoclonal reagents. , 1982, Cellular immunology.

[6]  G. Klein,et al.  Effect of different Epstein-Barr virus-determined antigens (EBNA, EA, and VCA) on the leukocyte migration of healthy donors and patients with infectious mononucleosis and certain immunodeficiencies. , 1982, Clinical immunology and immunopathology.

[7]  I. Ernberg,et al.  Use of cryopreserved lymphocytes for the indirect leukocyte migration inhibition assay. , 1981, Journal of immunological methods.

[8]  D. Levitt,et al.  Human B-lymphocyte subpopulations. I. Differentiation of density-separated B lymphocytes. , 1981, Clinical immunology and immunopathology.

[9]  I. Ernberg,et al.  Ultraviolet inactivation of Epstein--Barr virus-induced nuclear antigen (EBNA), DNA and IgM synthesis in human B lymphocytes. , 1981, Virology.

[10]  R. Warrington,et al.  Production of migration inhibition factor (MIF) by purified human T cell subpopulations. , 1981, Clinical and experimental immunology.

[11]  G. Klein,et al.  Membranes of EBV-carrying virus nonproducer cells inhibit leukocyte migration of EBV-seropositive but not seronegative donors. , 1981, Journal of immunology.

[12]  G. Klein,et al.  Leukocyte migration inhibition studies with Epstein-Barr virus (EBV) determined nuclear antigen (EBNA) in relation to the EBV-carrier status of the donor. , 1981, Cellular immunology.

[13]  E. Klein,et al.  EBV infection of mitogen‐stimulated human B lymphocytes , 1981, International journal of cancer.

[14]  G. Klein,et al.  Purification and biochemical characterization of the Epstein-Barr virus-determined nuclear antigen and an associated protein with a 53,000-dalton subunit , 1980, Journal of virology.

[15]  T. Révész,et al.  Leukocyte Migration Inhibition with Epstein‐Barr Virus Negative and Positive Cell Extracts , 1980, Allergy.

[16]  A G Bird,et al.  A New Approach to the Study of Human B Lymphocyte Function Using an Indirect Plaque Assay and a Direct B Cell Activator , 1979, Immunological reviews.

[17]  K. Krohn,et al.  Elaboration of leukocyte migration inhibitory factor by human lymphocyte subpopulations stimulated with mitogens. , 1978, Cellular immunology.

[18]  W. Weigle,et al.  B-lymphocytes activation by the Fc region of IgG , 1977, The Journal of experimental medicine.

[19]  H. Arvilommi,et al.  Leucocyte migration inhibitory activity in supernatants of cultured human mono-nuclear cells stimulated with mitogens or C3- and Fc-receptor reactions. , 1977, Immunology.

[20]  G. Klein,et al.  Polyclonal Ig production after Epstein-Barr virus infection of human lymphocytes in vitro , 1977, Nature.

[21]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[22]  R. Macdermott,et al.  Leukocyte inhibitory factor (LIF): production by purified human T and B lymphocytes. , 1975, Journal of immunology.

[23]  S. Wahl,et al.  Lymphokine production by C3b-stimulated B cells. , 1975, Journal of immunology.

[24]  S. Wahl,et al.  The role of macrophages in the production of lymphokines by T and B lymphocytes. , 1975, Journal of immunology.

[25]  B. Giovanella,et al.  An EBV-genome-negative cell line established from an American Burkitt lymphoma; receptor characteristics. EBV infectibility and permanent conversion into EBV-positive sublines by in vitro infection. , 1975, Intervirology.

[26]  J. Leikola,et al.  IgM Antibodies Specific for Epstein-Barr Virus in Infectious Mononucleosis without Heterophil Antibodies , 1974, British medical journal.

[27]  W. Henle,et al.  Epstein-barr virus specific diagnostic tests in infectous mononucleosis , 1974 .

[28]  R. Rocklin.  Products of activated lymphocytes: leukocyte inhibitory factor (LIF) distinct from migration inhibitory factor (MIF). , 1974, Journal of immunology.

[29]  G. Klein,et al.  SURFACE MARKERS ON HUMAN B AND T LYMPHOCYTES , 1973, The Journal of experimental medicine.

[30]  T. Yoshida,et al.  THE PRODUCTION OF MIGRATION INHIBITION FACTOR BY B AND T CELLS OF THE GUINEA PIG , 1973, The Journal of experimental medicine.

[31]  G. Klein,et al.  Cellular localization of an Epstein‐Barr virus (EBV)‐associated complement‐fixing antigen in producer and non‐producer lymphoblastoid cell lines , 1973, International journal of cancer.

[32]  P. Gerber,et al.  Induction of Cellular DNA Synthesis in Human Leucocytes by Epstein–Barr Virus , 1971, Nature.

[33]  R. Pulvertaft.  A study of malignant tumours in Nigeria by short-term tissue culture , 1965, Journal of clinical pathology.